BLAINJECTIONINJECTABLE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZIRABEV (bevacizumab-bvzr) by Pfizer is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2019.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIRABEV (bevacizumab-bvzr) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), a key driver of tumor angiogenesis and vascular permeability. It is a biosimilar to Avastin approved by the FDA in June 2019. The drug is used across multiple cancer indications where blocking new blood vessel formation to tumors is therapeutically beneficial.
$0.009BPart D
PeakZIRABEV is at peak lifecycle with modest Part D volume ($9M, 1,704 claims in 2023), indicating mature market penetration in a crowded VEGF-inhibitor space where biosimilar adoption remains competitive.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Started May 2025
0Non-small Cell Lung CancerMetastatic Colorectal CancerMetastatic Breast Cancer+5 more
Career Relevance
Working on ZIRABEV offers exposure to biosimilar commercialization, payer negotiations, and competitive market dynamics in oncology—critical skills as the industry shifts to biosimilars. However, modest sales volume ($9M) and intense competitive pressure mean smaller team size and lower career growth opportunity compared to higher-spending assets.
Worked on ZIRABEV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.